Joseph Hargett

Joseph Hargett

Despite hailing from the Greater Cincinnati, Ohio area, Joseph Hargett has spent nearly the past decade elbow-deep in Wall Street.  Specializing in financial writing, options strategies and stock-market analysis, Joseph cut his teeth in the research department of Cincinnati-based Schaeffer’s Investment Research.

While at Schaeffer’s, Joseph wrote market, stock and options commentary for SchaeffersResearch.com, and was lead editor for The Options Advisor (the nation’s leading options newsletter).

Joseph has since moved on to become a prolific Forbes contributor in the options realm, as well as a lead copy editor and contributor for a well respected investment newsletter publisher.  Joseph’s commentary has appeared in a plethora of media outlets, including The Wall Street JournalThe New York TimesMoney Show Digest, Reuters, CBE MarketWatch and Sentiment Magazine.

Recent Articles

Tuesday’s Vital Data: Apple Inc. (AAPL), Facebook Inc (FB) and Baxter International Inc (BAX)

Baird has bearish words for Apple (AAPL), Facebook (FB) options surge on resistance at $120 and Baxter International (BAX) scores bullish coverage.

Netflix, Inc.: Prepare for an Oversold NFLX Bounce

Support is looming large for NFLX stock, and Netflix shares are ready for a short-term bounce that traders can capitalize on.

Monday’s Vital Data: Tesla Motors Inc (TSLA), J C Penney Company Inc (JCP) and Teva Pharmaceutical Industries Ltd (ADR) (TEVA)

Earnings reports are driving heavy options activity for Tesla Motors (TSLA), JCPenney (JCP) and Teva Pharmaceuticals (TEVA).

Wednesday’s Vital Data: Bank of America Corp (BAC), Twitter Inc (TWTR) and Netflix, Inc. (NFLX)

Bank of America (BAC) options active as BAC stock rolls over, Twitter (TWTR) calls look for rebound from record lows and Netflix (NFLX) is rejected by resistance.

Tuesday’s Vital Data: Baidu Inc (ADR) (BIDU), Pfizer Inc. (PFE) and Valeant Pharmaceuticals Intl Inc (VRX)

Baidu (BIDU) put options pile on Chinese investigation, Pfizer (PFE) calls slip ahead of earnings and Valeant Pharmaceuticals (VRX) dives on investor commentary.